The global primary hyperoxaluria treatment market is expected to garner a market value of US$ 18 million in 2023 and is expected to accumulate a market value of US$ 41.07 million by registering a CAGR of 8.6% in the forecast period 2023 to 2033. The market for primary hyperoxaluria treatment registered a CAGR of 5.2% in the historical period 2018 to 2022.
Primary hyperoxaluria (PH) is a rare genetic disorder that affects the liver's ability to metabolize oxalate, leading to the formation of kidney stones and progressive kidney damage. The primary hyperoxaluria treatment market includes drugs and therapies aimed at reducing the production of oxalate in the body, managing symptoms, and preventing complications.
Some of the primary hyperoxaluria treatments available in the market include Lumasiran (Oxlumo), an RNA interference (RNAi) therapeutic that works by blocking the production of the enzyme that produces oxalate in the liver. The drug was approved by the FDA in 2020 for the treatment of PH type 1 in children and adults; Oxalate-degrading enzymes that can break down oxalate in the gut, reducing the amount of oxalate that is absorbed into the bloodstream; Kidney stone management and Dialysis and kidney transplant.
The primary hyperoxaluria treatment market is relatively small due to the rarity of the disease, but with the approval of Lumasiran, there is a growing focus on developing new therapies for the condition. Some companies currently working on PH treatments include Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, and Allena Pharmaceuticals.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 18 million |
| Anticipated Forecast Value (2033) | US$ 41.07 million |
| Projected Growth Rate (2023 to 2033) | 8.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Primary Hyperoxaluria Treatment reflected a value CAGR of 5.2% during the historical period, 2018 to 2022. One of the key drivers of market growth is the increasing prevalence of primary hyperoxaluria. While the condition is rare, its incidence has been steadily increasing in recent years, which is expected to drive demand for effective treatments.
The approval of Lumasiran in 2020 has also been a major boost to the market, as it represents the first targeted therapy for primary hyperoxaluria type 1. The drug has shown promising results in clinical trials, and its approval is expected to drive further research and development in the field.
In addition, the growing focus on precision medicine and personalized treatments is expected to drive innovation in the primary hyperoxaluria treatment market. With the increasing availability of genetic testing and personalized medicine, there is an opportunity to develop targeted therapies that are tailored to individual patients' genetic profiles.
The primary hyperoxaluria treatment market is expected to continue to grow in the coming years as new treatments are developed and approved, and as the demand for effective therapies for this rare disease continues to increase. Overall, the market for Primary Hyperoxaluria Treatment is expected to register a CAGR of 8.6% in the forecast period ranging from 2023 to 2033.
Increasing Prevalence of Primary Hyperoxaluria to push market growth
The increasing prevalence of primary hyperoxaluria is expected to be a significant driver of market growth in the primary hyperoxaluria treatment market. While the condition is considered rare, its incidence has been steadily increasing in recent years.
Primary hyperoxaluria is a genetic disorder that affects the liver's ability to metabolize oxalate, which can lead to the formation of kidney stones and progressive kidney damage. According to the National Institutes of Health (NIH), the estimated prevalence of primary hyperoxaluria ranges from 1 in 100,000 to 1 in 1,000,000 individuals worldwide.
However, recent studies have suggested that the actual prevalence of the condition may be higher than previously thought. For example, a study published in the American Journal of Kidney Diseases in 2019 estimated that the incidence of primary hyperoxaluria in the United States is closer to 1 in 45,000 individuals.
As the prevalence of primary hyperoxaluria continues to increase, there is likely to be greater demand for diagnosis and treatment of the condition, which is expected to drive growth in the primary hyperoxaluria treatment market. In addition, as more people are diagnosed with the condition, there is likely to be greater interest and investment in research and development of new treatments, which could further boost market growth.
Overall, the increasing prevalence of primary hyperoxaluria is expected to be a significant driver of market growth, as it is likely to lead to greater demand for effective treatments and increased investment in the development of new therapies.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
One of the significant challenges faced by the PKU therapeutics market is the lack of awareness and underdiagnosis of the disorder. Primary hyperoxaluria is a rare disease, and as a result, there is limited awareness of the condition among healthcare providers and the general public. This can lead to delays in diagnosis and treatment, which can negatively impact patient outcomes.
Moreover, developing new treatments for rare diseases such as primary hyperoxaluria can be challenging, as the regulatory environment can be complex and uncertain. This can lead to delays in bringing new therapies to market. Overall, while there have been some recent advances in the primary hyperoxaluria treatment market, there are still several challenges that need to be addressed to improve patient outcomes and ensure the development of more effective and accessible treatments.
Increasing awareness and diagnosis of the condition Shaping Landscape for Primary Hyperoxaluria Treatment in South & East Asia
The primary hyperoxaluria treatment market is still developing in the South & East Asia region, and there is limited data available on the prevalence and treatment of the condition in the region. However, there have been some recent developments that suggest that the market is starting to grow in this region.
For example, in 2020, the pharmaceutical company Alnylam Pharmaceuticals announced that its drug Lumasiran, the first targeted therapy for primary hyperoxaluria type 1, had received regulatory approval in Japan. This was a significant development, as Japan is a major market in the South & East Asia region and has a well-established healthcare system. The approval of Lumasiran in Japan is likely to increase awareness of primary hyperoxaluria in the region and could lead to greater demand for diagnosis and treatment of the condition.
In addition, there have been some recent studies that suggest that the prevalence of primary hyperoxaluria may be higher in certain parts of the South & East Asia region than previously thought. For example, a study published in the Journal of the American Society of Nephrology in 2020 found that the prevalence of primary hyperoxaluria type 1 was higher in parts of India than previously reported. This suggests that there may be a significant unmet need for primary hyperoxaluria treatment in the region.
Overall, while the primary hyperoxaluria treatment market is still developing in the South & East Asia region, recent developments suggest that there is growing interest and investment in this area. As awareness of the condition increases and more effective treatments become available, it is likely that the market will continue to grow in the region.
Increasing Focus on Technological Advancements shaping Landscape for Primary Hyperoxaluria Treatment in North America
The market for primary hyperoxaluria treatment in North America is expected to grow due to several factors. One of the primary drivers of market growth is the relatively high prevalence of primary hyperoxaluria in the region, particularly primary hyperoxaluria type 1. According to the National Institutes of Health (NIH), the estimated prevalence of primary hyperoxaluria type 1 in the United States is approximately 1 in 100,000 individuals. This high prevalence of the condition is expected to drive demand for effective treatments in the region.
Another factor that is contributing to market growth in North America is the increasing awareness and diagnosis of primary hyperoxaluria. There is growing recognition of the condition among healthcare professionals, which is leading to more accurate diagnosis and treatment of the condition. This is particularly true for primary hyperoxaluria type 1, which is often diagnosed in childhood. As more people are diagnosed with the condition, there is likely to be greater demand for effective treatments.
Advances in the development of treatments for primary hyperoxaluria are also driving market growth in North America. Lumasiran, a drug that targets the underlying genetic cause of primary hyperoxaluria type 1, was approved by the USA Food and Drug Administration (FDA) in 2020. This has led to greater interest and investment in the development of new therapies, which is expected to boost market growth.
In addition, favorable reimbursement policies in North America are making primary hyperoxaluria treatment more accessible to patients. For example, kidney transplantation, which is a treatment option for some patients with end-stage renal disease caused by primary hyperoxaluria, is typically covered by insurance in North America. This makes it easier for patients to access the treatment they need.
Finally, North America has a strong healthcare infrastructure that is able to support the development and delivery of new treatments for primary hyperoxaluria. This includes specialized centers for the treatment of rare diseases, which can provide comprehensive care for patients with the condition. The strong healthcare infrastructure in North America is expected to contribute to continued growth in the primary hyperoxaluria treatment market in the region.
Overall, the combination of high prevalence, increasing awareness and diagnosis, advances in treatment options, favorable reimbursement policies, and a strong healthcare infrastructure is expected to drive growth in the primary hyperoxaluria treatment market in North America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Parenteral route of administration to hold a significant share and push market growth
The injectable route of administration is likely to account for a significant share of the Primary Hyperoxaluria Treatment market. Currently, the only approved therapy for the treatment of primary hyperoxaluria is Lumasiran, which is administered via subcutaneous injection. Therefore, the subcutaneous injection route of administration is expected to account for a significant share of the primary hyperoxaluria treatment market.
However, there are also other therapies currently in development for the treatment of primary hyperoxaluria that may use different routes of administration. For example, some gene therapy approaches are being developed that would involve the delivery of a therapeutic gene via a viral vector. These therapies may use an intravenous infusion or other routes of administration. Overall, while the subcutaneous injection route of administration is currently dominant in the primary hyperoxaluria treatment market, the development of new therapies may lead to the use of different routes of administration in the future.
Hospital pharmacies segment to hold a significant share and push market growth
Hospitals and specialty clinics are often the first point of contact for patients with Primary Hyperoxaluria, as they provide specialized care and access to diagnostic tools and treatments. These facilities also have the expertise and resources to provide comprehensive care to patients with complex or severe cases of Primary Hyperoxaluria.
In addition, many of the treatments for Primary Hyperoxaluria require specialized administration or monitoring, such as intravitreal injections or electroretinography testing, which are typically performed in hospitals or specialty clinics. This further contributes to the dominance of these distribution channels in the Primary Hyperoxaluria Treatment market.
Overall, hospitals and specialty clinics are likely to continue to account for a significant share of the Primary Hyperoxaluria Treatment market, driven by the specialized care and expertise they provide. However, as patient preferences and healthcare delivery models continue to evolve, the market share of the various distribution channels may shift over time.
Key players in the market include companies such as Competition Deep Dive, Alnylum Pharma, OxThera, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co Ltd, Genentech, along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 18 million |
| Market Value in 2033 | US$ 41.07 million |
| Growth Rate | CAGR of 8.6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market value reaches US$ 18 million in 2023.
The market is anticipated to surpass US$ 41.07 million by 2033, with a CAGR of 8.6%.
Advancing innovative enzyme replacement therapies is the current market trend.
The United States shines as a lucrative primary hyperoxaluria treatment hub.
The market experienced a CAGR of 5.2% between 2018 and 2022.
1. Executive Summary | Primary Hyperoxaluria Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Type 1
5.3.2. Type 2
5.3.3. Type 3
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
6.3.1. Pyridoxine
6.3.2. Potassium Citrate
6.3.3. Thiazides
6.3.4. Orthophosphates
6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration , 2023 to 2033
7.3.1. Oral
7.3.2. Intravenous
7.4. Y-o-Y Growth Trend Analysis By Route of Administration , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Route of Administration , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital pharmacies
8.3.2. Retail pharmacies
8.3.3. Online pharmacies
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East & Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. United States
10.2.1.2. Canada
10.2.2. By Type
10.2.3. By Drug Class
10.2.4. By Route of Administration
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Drug Class
10.3.4. By Route of Administration
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Type
11.2.3. By Drug Class
11.2.4. By Route of Administration
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Drug Class
11.3.4. By Route of Administration
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Type
12.2.3. By Drug Class
12.2.4. By Route of Administration
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Drug Class
12.3.4. By Route of Administration
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Type
13.2.3. By Drug Class
13.2.4. By Route of Administration
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Drug Class
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Type
14.2.3. By Drug Class
14.2.4. By Route of Administration
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By Drug Class
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Type
15.2.3. By Drug Class
15.2.4. By Route of Administration
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Type
15.3.3. By Drug Class
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Type
16.2.3. By Drug Class
16.2.4. By Route of Administration
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Type
16.3.3. By Drug Class
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Type
17.1.2.2. By Drug Class
17.1.2.3. By Route of Administration
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Type
17.2.2.2. By Drug Class
17.2.2.3. By Route of Administration
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Type
17.3.2.2. By Drug Class
17.3.2.3. By Route of Administration
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Type
17.4.2.2. By Drug Class
17.4.2.3. By Route of Administration
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Type
17.5.2.2. By Drug Class
17.5.2.3. By Route of Administration
17.5.2.4. By Distribution Channel
17.6. United kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Type
17.6.2.2. By Drug Class
17.6.2.3. By Route of Administration
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Type
17.7.2.2. By Drug Class
17.7.2.3. By Route of Administration
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Type
17.8.2.2. By Drug Class
17.8.2.3. By Route of Administration
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Type
17.9.2.2. By Drug Class
17.9.2.3. By Route of Administration
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Type
17.10.2.2. By Drug Class
17.10.2.3. By Route of Administration
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Type
17.11.2.2. By Drug Class
17.11.2.3. By Route of Administration
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Type
17.12.2.2. By Drug Class
17.12.2.3. By Route of Administration
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Type
17.13.2.2. By Drug Class
17.13.2.3. By Route of Administration
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Type
17.14.2.2. By Drug Class
17.14.2.3. By Route of Administration
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Type
17.15.2.2. By Drug Class
17.15.2.3. By Route of Administration
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Type
17.16.2.2. By Drug Class
17.16.2.3. By Route of Administration
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Type
17.17.2.2. By Drug Class
17.17.2.3. By Route of Administration
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Type
17.18.2.2. By Drug Class
17.18.2.3. By Route of Administration
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Type
17.19.2.2. By Drug Class
17.19.2.3. By Route of Administration
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Type
17.20.2.2. By Drug Class
17.20.2.3. By Route of Administration
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Type
17.21.2.2. By Drug Class
17.21.2.3. By Route of Administration
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Type
18.3.3. By Drug Class
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Alnylum Pharma
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. OxThera
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Dicerna Pharmaceuticals, Inc.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Allena Pharmaceuticals
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Biocodex
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Tecoland Corporation
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Zhejiang Tianxin Pharmaceutical Co.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Takeda Pharmaceuticals
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Wuxi Further Pharmaceutical Co Ltd
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Genentech
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Healthcare
February 2023
REP-GB-16623
299 pages
Explore Healthcare Insights
View Reports
Primary Hyperoxaluria Treatment Market
